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Abstract
Autoimmune diseases (ADs) represent a diverse collection of diseases in terms of their demographic proﬁle and primary
clinical manifestations. The commonality between them however, is the damage to tissues and organs that arises from the
response to self-antigens. The presence of shared pathophysiological mechanisms within ADs has stimulated searches for
common genetic roots to these diseases. Two approaches have been undertaken to sustain the “common genetic origin”
theory of ADs. Firstly, a clinical genetic analysis showed that autoimmunity aggregates within families of probands diagnosed
with primary Sjo ¨gren’s (pSS) syndrome or type 1 diabetes mellitus (T1D). A literature review supported the establishment
of a familiar cluster of ADs depending upon the proband’s disease phenotype. Secondly, in a same and well-deﬁned
population, a large genetic association study indicated that a number of polymorphic genes (i.e. HLA-DRB1, TNF and
PTPN22) inﬂuence the susceptibility for acquiring different ADs. Likewise, association and linkage studies in different
populations have revealed that several susceptibility loci overlap in ADs, and clinical studies have shown that frequent
clustering of several ADs occurs. Thus, the genetic factors for ADs consist of two types: those which are common to many
ADs (acting in epistatic pleitropy) and those that are speciﬁc to a given disorder. Their identiﬁcation and functional
characterization will allow us to predict their effect as well as to indicate potential new therapeutic interventions. Both
autoimmunity family history and the co-occurrence of ADs in affected probands should be considered when performing
genetic association and linkage studies.
Keywords: Sjo ¨gren’s syndrome, Type 1 diabetes mellitus, rheumatoid arthritis, systemic lupus erythematosus, genetics,
inheritance patterns
Introduction
Autoimmune diseases (ADs) are chronic conditions
initiated by a loss of immunological tolerance to self-
antigens. The chronic nature of such diseases has a
signiﬁcant impact in terms of the utilization of medical
care, direct and indirect economic costs and quality of
life. The estimated incidence of ADs is about 90 cases
per 100,000 person-year and their prevalence is about
3% of the population (Cooper and Stroehla 2003).
Almost all ADs disproportionately affect middle age-
women and are among the leading causes of death for
this group of patients. The older the patient, the lower
the male:female ratio becomes (Cooper and Stroehla
2003).
Although the etiology of ADs is unknown, these
diseases are known to feature genetic and environ-
mental factors in their development (Anaya et al.
2005; Vyse and Todd 1996). The impact of genetic
predisposition on susceptibility to ADs was ﬁrst
identiﬁed by the analysis of disease concordance
rates in monozygotic twins. The monozygotic disease
concordance rate ranges from about 15% for
rheumatoid arthritis (RA) (Silman et al. 1993) to a
fairly robust 57% for systemic lupus erythematosus
(SLE) (Winchester 1992) climate. Comparisons of
these high concordance rates with disease incidence in
the general population predict that genetic predis-
position is the dominant factor in AD susceptibility.
The dramatic decrease in the concordance rate of
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supports the presence of multiple genes contributing
to the genetic predisposition. Finally, the estimation
of familial aggregation, or recurrent risk ratio (lR)
for ADs (which is the ratio of the risk of disease
prevalence among the speciﬁc-relative pairs (R)o f
affected probands to the prevalence of the disease in
the general population), supports a fundamental role
for genetic predisposition in disease susceptibility
(Anaya et al. 2005). However, population studies have
established that each population holds a mutational
pool, in which most mutations (i.e. polymorphisms)
have mild or even undetectable effects individually,
but in combination with other alleles may promote or
protect from, autoimmune phenomena. Such inter-
play between genetic variants will generate a change
in the measurable risk of developing an autoimmune
phenotype. This characteristic is the main reason
why ADs are not inherited in a simple, classical
Mendelian way, but instead have a complex or an as
yet unknown mode of inheritance (Vyse and Todd
1996).
As a group, ADs represent a diverse collection of
diseases in terms of their demographic proﬁle and
primary clinical manifestations. The commonality
between them, however, is the damage to tissues and
organs that arises from the response to self-antigens
(loss of tolerance). The vast majority of research
generally focuses strongly on individual clinical
diseases even though these autoimmune phenotypes
could represent pleiotropic outcomes of speciﬁc,
common disease genes that underlie similar immuno-
genetic mechanisms (Anaya et al. 2005). Therefore,
our group is investigating in a well-deﬁned population
whether or not clinically different ADs share the same
susceptibility risk factors (i.e. genetic variants). This
hypothesis of a common genetic origin for diverse
ADs has been sustained by two important ﬁndings.
The ﬁrst consisted of a clinical analysis in which
aggregation of ADs was observed in families of
patients with primary Sjo ¨gren’s syndrome (pSS) and
type 1 diabetes mellitus (T1D). The second was a
large genetic association study carried out in three
different ADs namely RA, SLE and pSS. Herein, we
summarize the main results of these and other similar
studies that reveal new insights concerning the
inheritance pattern and the genetic risk factors for
the development of ADs.
Genetic history of the sample population
Historical and genetic evidence suggests that the
population of Antioquia is useful for the genetic
mapping of complex traits. The state of Antioquia
(capital, Medellı ´n) is geographically located in the
north-western part of Colombia between the Central
and Western branches of the Andean Mountains and
is inhabited by the “Paisa” community, a description
of which has already been published (Bravo et al.
1996; Jimenez et al. 1996). Anthropological and
historical studies describe this population as the most
clearly deﬁned in Colombia. Its ethno-historical
origin stems most probably from the Spaniards,
Jews (Christianized Sephardim or Marranos), and
Basques. The admixture between Paisa and African
or Amerindian populations has been historically
documented as low (Parsons 1968). Several lines of
genetic evidence suggest that the Paisa community
exhibits the features of a genetically isolated
community. Firstly, the identity coefﬁcient method
has estimated the ancestral ethnic components as
85% Caucasian and 15% Amerindian (Bravo et al.
1996). The African contribution to the Paisa
community was estimated as being not signiﬁcantly
different from 0 (Jimenez et al. 1996). Secondly,
strong admixture distortions in the gender vectors of
racial blending in this community were found, with
more than 96% of the chromosomes being of
Caucasian origin and most of the mitochondrial
component of Amerindian origin (Carvajal-Carmona
et al. 2000).
Familial aggregation of autoimmunity
Primary SS is a late-onset AD characterized by a
lymphocytic and plasma cell inﬁltration of the
exocrine glands, as well as by the production of
autoantibodies leading to dryness of mucosa, mainly
oral and lachrymal (Anaya et al. 2001). Contrary to
pSS, T1D appears early in life as a consequence
of autoimmune damage to the insulin-producing
pancreatic b cells (Expert Committee on the
Diagnosis and Classiﬁcation of Diabetes Mellitus
1997). There is strong evidence indicating familial
clustering of various ADs in patients with several
ADs including pSS and T1D (Anaya et al. 2006a, c)
(Table I).
Bloch and Bunin ﬁrst suggested a shared immuno-
pathological mechanism for SS, SLE, systemic
sclerosis (SSc) and autoimmune thyroid diseases
(AITD), as well as a possible familial aggregation of
these diseases in pSS patients (Bloch and Bunim
1963). They described the clinical and immunological
characteristics of 57 cases of SS and some immuno-
logical abnormalities among their relatives. However,
most of those patients (70%) had secondary SS (Bloch
and Bunim 1963). In fact, SS may coexist with other
ADs such as RA (Moutsopoulos et al. 1979), SLE
(Steinberg and Talal 1971), AITD (Foster et al.
1993), and SSc (Alarcon-Segovia et al. 1974). Later,
Reveille et al (1984) examined the presence of ADs in
family members of 51 patients with pSS. They
investigated the relationships of HLA genes and
heavy chain immunoglobulin (Gm) haplotypes to
disease and autoantibody expression in six large
kindreds, each having one or more memberswith pSS.
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PD No. of families Type of study Aggregated disease Population Observations References
ADs 265 Multiplex families T1D, RA, SLE MADGC AD Core: RA, SLE, T1D,
MS, AITD, JRA, IBD, PSO,
pSS
Criswell et al. (2005)
ADs Review analysis MS with AITD, ADD,
SLE, pSS
AITD co-ocurrence Sloka (2002)
JRA 164 Affected-Sibbling pairs AITD USA Moroldo et al. (2004)
JRA 110 cases 45 control Case-control family AITD USA Autoimmunity prevalence higher
in FDR than in SDR
Prahalad et al. (2002)
MS 571 Case-control family study AITD Caucasian-UK lS ¼ 1.65 Broadley et al. (2000)
MS 357 Multiplex families MS, T1D, AITD, VIT French Heinzlef et al. (2000)
pSS 2 patients Case report Connective tissue diseases Japanese HLA haplotypes do not explain
alone autoimmunity
Moriuchi et al. (1986)
pSS Twin patients and
their mother
Case report pSS and Immunological
diseases
All pSS, similar clinical,
serological data and
histological data.
History of immunological
disorders
Bolstad et al. (2000)
pSS 98 Multiplex families AITD, SLE, pSS, MS, SSc Signiﬁcant sex effect Reveille et al. (1984)
pSS 101 patients 124
controls
Multiplex families AITD, SLE, RA Colombian SSc and AITD correlated with
proband’s phenotype
Anaya et al. (2006c)
RA 11 patients Gene expression array
proﬁles on FDR
SLE, RA, MS, T1D USA Transcript levels are associated
with family resemblance
Maas et al. (2005)
RA 257 patients Genomewide screen in
multiplex families
RA, SLE, IBD, AS USA Allele sharing for HLA and
other regions
Jawaheer et al. (2001)
SLE 11 patients Gene expression array
proﬁles on FDR
SLE, RA, MS, T1D USA Transcript levels are associated
with family resemblance
Maas et al. (2005)
SLE 154 cases 140 controls Multicentric retrospective
case-control study
SLE Italian SLE FDR susceptibility risk
increased
Priori et al. (2003)
SLE 118 patients Multicase SLE families SLE, MS, RA Caucasian Higher prevalence of AD in
relatives of Probands
Corporaal et al. (2002)
SLE 12 twin pairs Case report lMZ ¼ 57; DZ were discordant
for SLE
Block et al. (1975)
SLE 1214 patients Multiplex families RA GLADEL lS ¼ 1.5 Alarcon-Segovia et al. (2005)
T1D 505 families Affected-sibling families T1D UK Parents AD prevalence higher
compared to the population
Tait et al. (2004)
TID 98 patients 113 controls Multiplex families AITD, T1D Colombian lS ¼ 2.21 ADs taken together Anaya et al. (2006a)
VIT 2624 patients Multiplex families VIT, AITD, PA, ADD, SLE USA-UK Caucasian lS ¼ 6.1 Alkhateeb et al. (2003)
VIT 133 patients Multiplex families AITD, RA, PSO, T2D,
ADD, PA
Caucasian-UK and USA lS ¼ 6.34 Laberge et al. (2005)
PD, proband’s disease; MADGC, Multiple Autoimmune Disease Genetics Consortium; GLADEL, Grupo Latinoamericano de Estudio del Lupus Eritematoso Siste ´mico; AD, autoimmune disease; pSS,
primary Sjogren’s syndrome; T1D, type 1 diabetes mellitus; AITD, autoimmune thyroid diseases; SLE, systemic lupus erythematosus; RA, rheumatoid arthritis; SSc, systemic sclerosis; PBC, primary
biliary cirrhosis; VIT, vitiligo; MS, multiple sclerosis; PSO, psoriasis; T2D, type 2 diabetes; ADD, Addison’s disease; IBD, inﬂammatory bowel disease.
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7Segregation analyses suggested aMendelian dominant
genetic effect common among the many ADs and
serologic reactions that were not linked to HLA or Gm
(Reveille et al. 1984). Recently, we performed a
familial aggregation study of ADs in 101 families of
pSS patients and 124 control families (Anaya et al.
2006c). In the families of pSS patients, 38 (37.6%)
had at least one ﬁrst degree relative (FDR) with an
AD, compared with 27 (21.8%) of control families
(OR 2.2, 95% CI: 1.2–3.9, p ¼ 0.01). Similarly to
Reveille et al, we found that AITD, RA, and SLE were
the most common ADs among relatives of the pSS
patients (Reveille et al. 1984; Anaya et al. 2006c).
Multiple sclerosis and SSc were also observed,
although with lower frequency. Moreover, the risk of
familial autoimmunity increased with the number of
affected FDR (Anaya et al. 2006c). Familial aggrega-
tion of AITD, SLE, RA, T1D, vitiligo (VIT), and all
ADs taken together as a single trait, was observed
(Anaya et al. 2006c).
Familial autoimmunity was also investigated in 98
T1D families and 113 families of healthy control
individuals all from the same Colombian population
(Anaya et al. 2006a). Our results showed that in the
families of T1D patients, 25 (25.5%) presented at
least one FDR having an AD compared with 9 (8%)
in control families (OR: 3.96, 95% CI: 1.75–9;
p ¼ 0.0006), supporting the ﬁndings of Tait et al
(2004) who observed a similar increase of ADs in
family members of British patients with T1D. In our
cohort, familial aggregation was observed for AITD,
T1D and all ADs taken together as a single trait
(Anaya et al. 2006a). Of particular interest, AITD
(mainly hypothyroidism) is the most common AD
encountered among FDR of pSS and T1D patients;
this has also been reported in familial studies in
multiple sclerosis (Broadley et al. 2000), VIT
(Alkhateeb et al. 2003), juvenile RA (JRA) (Prahalad
et al. 2002), and SLE (Priori et al. 2003). The next
most common diagnosed ADs in FDR of pSS
patients are RA and SLE, while in T1D SLE ﬁlls
this position (Anaya et al. 2006a, c). All these
diseases, as we will discuss, share similar suscepti-
bility gene polymorphisms including HLA and non-
HLA variants (Becker et al. 1998; Wandstrat and
Wakeland 2001; Correa et al. 2005; Gomez et al.
2005), which may account for aggregation. In fact,
shared genetic factors are the most likely cause of
familial aggregation; however, it is important to
keep in mind that shared environmental factors can
also contribute to such aggregation. For a speciﬁed
relative type, a lR . 1.0 suggests familial aggregation
of the disease, but does not identify whether genetic
or environmental factors are aggregating (Laird and
Cuenco 2003). Thus, familial aggregation studies
should be control studies in which population
matched proband families lacking the trait of interest
should be included.
Maternal transmission of the autoimmunity trait
A predominant inheritance of the autoimmunity trait
from mothers has been observed in patients with pSS
(Reveille et al. 1984; Anaya et al. 2006c), SLE (Priori
et al. 2003) and T1D (Tait et al. 2004), indicating a
plausible and preferential transmission of suscepti-
bility alleles from mothers to offspring. Maternal
transmission of autoimmunity could be inﬂuenced by
the high preponderance of ADs in females compared
to the general population. However, this higher than
expected frequency of the autoimmunity trait
maternal transmission would warrant further studies
of mtDNA, genomic imprinting, maternal-offspring
compatibility, and indirect genetic effects.
Collectively, results indicate that in pSS, T1D
as well as in other ADs, pathologic autoimmunity
aggregates as a trait (Table I), and emphasize the
importance of the autoimmunity family history as a
substantial risk factor for the development of any AD.
This summary also points out the magnitude of the
autoimmunity family history when carrying out both
linkage and association genetic studies (i.e. trans-
mission disequilibrium test).
Population genetic evidence for the common
origin of ADs
The autoimmune phenotype and genotype might
vary among populations. Diverse populations
would behave genetically different when referring to
its genetic variants, depending on the population
natural and epidemiological history (Mori et al.
2005). In addition, the effects of genotype on
phenotype in any given population may depend
upon environment and the length of exposure to an
undeﬁned etiological insult. Therefore, there is a need
to explore genetic associations in diverse populations.
Conﬁrming the results within different populations
favors a more complete and homogeneous compre-
hension of the pathogenic mechanisms of ADs.
The “common variants/multiple disease (CV/MD)”
hypothesis implies that “complex phenotypes are not
unique entities but are mosaics of common disease
speciﬁc alleles and non-disease speciﬁc modifying
alleles in the population, inﬂuenced by a vast array of
environmental factors” (Becker 2004). We surmise
that if the CV/MD hypothesis was to be validated in an
autoimmune setting, it would provide a convincing
framework for the possibility that a common set of
alleles might contribute to dissimilar clinical
phenotypes.
In order to further investigate the common origin
for diverse ADs we examined the polymorphisms of 10
genes in different ADs in a Northwestern Colombian
population. These genes were chosen by their
important participation in autoimmune response and
inﬂammation (Table II). Our results demonstrated
J.-M. Anaya et al. 188that the HLA-DRB1 gene, TAP2*0201, TNF2, and
PTPN22 1858T alleles signiﬁcantly inﬂuence the
susceptibility for acquiring diverse ADs, while variants
of CCR5 and NOS3 genes inﬂuence the development
of a particular AD (such as SLE: Table II).
Furthermore, we have found that NFKBIL1 gene
polymorphisms behave as protective factors for the
development of SLE and pSS, while IL1B poly-
morphism protect against the development of SLE
only (Table II). Taken together, our results clearly
indicate that in a single, carefully-characterized
population, some polymorphisms are common risk
factors for the development of ADs while others are
disease speciﬁc (Figure 1).
Independentreversegeneticstudieshavealsoshown
that other polymorphic genes could inﬂuence the
susceptibility to acquire multiple ADs (i.e. CTLA4,
CARD15,FCGR2A,FCRL3,IFNG,NOS2A,PARP1,
PDCD1, RUNX1, MIF) (Oertelt et al. 2005; Yamada
and Ymamoto 2005; Pearce and Merriman 2006;
Serrano et al. 2006). Findings from the Multiple
Autoimmune Disease Genetics Consortium
(MADGC) have also shown that clinically distinct
autoimmune phenotypes might share a common set of
susceptibility genes (Criswell et al. 2005). Likewise,
results from linkage studies in different populations
have shown analogous results, which are summarized
in Table III.
Figure 1. The common origin for diverse ADs hypothesis. ADs are the result of multiple interactions of polymorphic genes and
environmental or stochastic factors leading to a loss of immunological tolerance to self-antigens and then to tissue damage. The genetic risk
factors for ADs may well consist of two forms: those which are common to many ADs acting in pleitropy, and those that are speciﬁc to a given
disorder. SLE: systemic lupus erythematosus, SS: Sjo ¨gren’s syndrome, RA: rheumatoid arthritis.
Table II. Genetic polymorphisms associated with ADs in Northwestern Colombians.
Gene Location AD Associated variant OR (95% CI) p-value References
HLA-DRB1 6p21.3 RA HLA-DRB1*0404 3.7 (1.73–7.83) 0.0009 Anaya et al. (2002a)
HLA-DQB1 6p21.3 pSS HLA-DRB1*0301-DQB1*0201 4.3 (1.6–11.9) 0.001 Anaya et al. (2002b)
SLE HLA-DRB1*0301-DQB1*0201 3.12 (1.45–6.73) 0.003 Anaya et al. (2006b)
TAP2 6p21.3 SLE TAP2*0201 2.0 (1.22–3.30) 0.03 Anaya et al. (2002b)
RA TAP2*0201 3.0 (1.5–5.6) 0.002 Anaya and Correa (2000)
TNF 6p21.3 RA TNF-308A 1.8 (1.26–2.54) 0.002 Correa et al. (2005)
SLE TNF-308A 2.6 (1.77–3.83) 0.0001
pSS TNF-308A 2.9 (1.90–4.57) 0.0001
NFKBIL1 6p21.3 SLE IKBL þ 738T 0.45 (0.24–0.83) 0.016 Castiblanco and Anaya (2006)
pSS IKBL þ 738T 0.38 (0.18–0.74) 0.008
SLE IKBL-62A 0.59 (0.43–0.79) 0.0004
NOS3 7q36.1 SLE Intron 4b 2.2 (1.29–3.60) 0.005 Serrano et al. (2004)
PTPN22 1p13.2 SLE 1858T 2.58 (1.49–4.39) 0.001 Gomez et al. (2005)
pSS 1858T 2.42 (1.24–4.75) 0.01
T1D 1858T 1.83 (0.98–3.42) 0.06
CCR5 3p21.31 SLE HHE haplotype 1.98 (1.12–3.53) 0.001 Herrera et al. (2004)
HHG*2 haplotype 2.55 (1.69–3.85) 0.001
IL1B 2q13 SLE þ3953T 0.57 (0.34–0.88) 0.01 Camargo et al. (2004)
RA, rheumatoid arthritis; SS, Sjo ¨gren’s syndrome; SLE, systemic lupus erythematosus; T1D, Type 1 diabetes mellitus.
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AD
Chr. SLE RA AITD MS T1D IBD
1 1q41 (Graham et al. 2001) 1p13, 1q43 (Jawaheer
et al. 2003)
1p21.3 (Becker et al. 1998) 1q42 (Cox et al. 2001)
1p36, 1p13, 1q42 (Gaffney et al. 1998) 1p34 (Pericak-Vance et al. 2004)
1q23 (Tsao et al. 2002)
2 2q37 (Lindqvist et al. 2000) 2p11 (D’Alfonso et al. 1999) 2q31-34 (Myerscough
et al. 2000)
2q32.3 (Duerr et al.
2000)
2p15, 2q21-33 (Gaffney et al. 1998) 2q31 (Cox et al. 2001)
3 3cent-q11 (Gaffney et al. 1998) 3p21.2, 3p14.1, 3p13
(Becker et al. 1998)
3q13.12 (Duerr et al.
2000)
3p14 (Pericak-Vance et al.
2004)
3q21.1 (D’Alfonso et al. 1999)
4 4q28 (Gaffney et al. 1998)
4q15-13 (Lindqvist et al. 2000)
5 5q14.3-15 (Namjou et al. 2005) 5q14.3-15 (Namjou et al.
2005)
5p14-12 (Kuokkanen et al. 1997) 5q33-q35 (Ma et al.
1999)
5p14 (Dyment et al. 2001)
5p12-13 (Mellai et al. 2003)
5p (Oturai et al. 1999)
6 6q (Koskenmies et al. 2004) 6q (Eyre et al. 2004) 6p (Tomer et al. 2003) 6p (Mellai et al. 2003) 6q27 6p21 (Cox et al.
2001)
6p11-21 (Gaffney et al. 1998) 6p21.3 (Jawaheer et al.
2003)
6p22.3-14.1 (Alkhateeb
et al. 2002)
6p21 (Kuokkanen et al. 1997) 6q25-27 (Myerscough
et al. 2000)
6p21.3 (Dyment et al.
2001)
6p21 (Oturai et al. 1999)
6p21, 6q (Fisher et al.
2003)
7 7q (Tomer et al. 2003) 7p15.2, 7q11.21 (Becker et al.
1998)
7p15.2, 7q31.31 (Becker
et al. 1998)
7p15.2 (Becker et al.
1998)
7p15.2 (D’Alfonso et al. 1999) 7q32.1 (Duerr et al.
2000)
8 8q (Tomer et al. 2003) 8q24 (Sale et al. 2002)
9 9p22 (Lindqvist et al. 2000) 9p22 (Jawaheer et al.
2003)
10 10q21 (Jawaheer et al.
2003)
10q (Tomer et al. 2003) 10q26.3 (Becker et al. 1998) 10q26.3 (Becker et al. 1998)
10p11 (Cox et al. 2001)
11 11p15 (Gaffney et al. 1998) 11p15.5 (Becker et al. 1998) 11p15.5 (Becker et al. 1998)
11p15 (Cox et al. 2001)
12 12q12 (Jawaheer et al.
2003)
12p13.12 (Becker et al. 1998) 12p13.12 (Becker et al. 1998) 12q (Duerr et al. 2000)
12p (Fisher et al. 2003)
13 13q (Becker et al. 1998) 13q (Becker et al. 1998)
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AD
Chr. SLE RA AITD MS T1D IBD
14 14q (Koskenmies et al. 2004) 14q (Tomer et al. 2003) 14q11-12 (Duerr et al.
2000)
14q21-23 (Gaffney et al. 1998) 14q11.2
(Ma et al. 1999)
15 15q26 (Gaffney et al. 1998)
16 16q22 (Tsao et al. 2002) 16cen (Fisher et al.
2003)
16q22 (Cox et al. 2001) 16q12.1 (Duerr et al.
2000)
16q13 (Gaffney et al. 1998) 16p (Eyre et al. 2004)
17 17q13 (Jawaheer et al.
2003)
17p13.3 (Becker et al. 1998) 17p13.3 (Becker et al. 1998)
17q (Larsen et al. 2000)
17q22-24 (Kuokkanen et al.
1997)
17q12 (Dyment et al. 2001)
18 18q21 (Jawaheer et al.
2003)
18q21 (Vaidya et al. 2000) 18q22.2 (Duerr et al.
2000)
19 19q13 (Becker et al. 1998) 19q13 (Becker et al. 1998)
19q13 (Lindqvist et al. 2000) 19q13 (Pericak-Vance et al. 2004)
20 20p12 (Gaffney et al. 1998) 20q (Tomer et al. 2003)
21
22 22q13.1 (D’Alfonso et al. 1999)
X Xp11.1 (Becker et al. 1998) Xp11.1 (Becker et al. 1998)
MS, multiple sclerosis; SLE, systemic lupus erythematosus; T1D, type 1 diabetes; RA, rheumatoid arthritis; AITD, autoimmune thyroid diseases; IBD, inﬂammatory bowel disease.
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1The aforementioned ﬁndings indicate that ADs
might be the consequence of pleiotropic effects of
speciﬁc genes on a common polygenic background
(Reveille et al. 1984; Bias et al. 1986; Lin et al. 1998).
Strong suggestions from previous studies allow us
to point out the major histocompatibility complex,
including both HLA and non-HLA loci, as one of the
central loci contributing to pSS, T1D and other ADs
(Vyse and Todd 1996; Wandstrat and Wakeland
2001). However, not all ADs share the same genetic
susceptibility or allelic spectrum. Thus, the genetic
risk factors for ADs may well consist of two forms:
those which are common to many ADs and those that
are speciﬁc to a given disorder (Figure 1).
Conclusion and perspectives
Herein, we have uncovered two approaches support-
ing the hypothesis of a common genetic origin for
diverse ADs. A familial core for ADs depending upon
the proband phenotype is illustrated as a graphic
contingency table in Figure 2, and the chromosomal
regions overlapping among the most frequent ADs
are depicted in Figure 3. The precise mechanisms by
which possession of the genetic variants affect diverse
ADs are not completely understood and are beyond
the scope of this review. However, genetic variation
plays an important role in the determination of
individual changes in protein expression as discussed
elsewhere (Price et al. 1999; Camargo et al. 2004;
Knight 2005; Castiblanco and Anaya 2006; Serrano
et al. 2006). Since variation in gene expression is
heritable and can be mapped as a quantitative trait,
haplotype structures and functional assays should be
considered in such genetic studies.
The co-occurrence of ADs is a well-known
phenomenon. Epidemiological studies have described
an increased statistical susceptibility of people with
one AD to develop other ADs (Sloka 2002). This
Figure 2. Familial autoimmunity clusters. The ordinate represents
the proband’s disease, while the axis despites the correspondent
aggregated AD. Circle size represents the weighted analyzed reports
and does not necessarily indicate the aggregation’s magnitude. This
ﬁgure was generated from Table I data. JRA, juvenile rheumatoid
arthritis; MS, multiple sclerosis; SS, Sjo ¨gren’s syndrome; RA,
rheumatoid arthritis; SLE, systemic lupus erythematosus; T1D,
type 1 diabetes mellitus; VIT, vitiligo; AITD, autoimmune thyroid
diseases; ADD, Addison’s disease; IBD, inﬂammatory bowel
disease; SSc, systemic sclerosis.
Figure 3. Chromosome regions overlap among ADs. The ordinate represents the AD, while the axis despites the chromosomal region
intervals. This ﬁgure was generated from table III data. AITD: autoimmune thyroid diseases, IBD, inﬂammatory bowel disease; MS, multiple
sclerosis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; T1D, type 1 diabetes mellitus.
J.-M. Anaya et al. 192situation is well illustrated by the type 2 autoimmune
polyglandular syndrome, originally described by
Schmidt (1926), and by the “multiple autoimmune
syndrome”, described by Humbert and Dupond
(1988). In these scenarios a single genotype is
responsible for diverse phenotypes, making these
cases the “magna prove” for a common origin of ADs.
Recently, Namjou et al. (2005) after stratiﬁcation of
multiplex SLE pedigrees by the presence of AITD,
observed that 5q14.3–15 is a region linked to both
diseases. Thus, besides autoimmunity family history,
the co-occurrence of ADs should be also considered
when performing association and linkage studies.
The common genetic background evidence for ADs
has grown and allows us to infer that AD phenotypes
have aclinicalbehaviour that can be independent from
their genetic causes. The heterogeneity of ADs could
be due to a collection of diverse disorders based on
epidemiologypathologyordiagnosticresultsbutinfact
the underlying immunogenetic mechanism might be
similar. Identiﬁcation of such common genetic causes
will enhance our understanding of the common
mechanismsofthesecomplex,frequentandsometimes
devastating diseases and will permit us to predict them
as well as to discover new therapeutic interventions.
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